CureToday: UC enrolling patients for glioblastoma trial

A new clinical trial at the University of Cincinnati is studying the effectiveness of a new two-pronged immunotherapy treatment procedure to treat the most aggressive and deadly type of brain tumors, called glioblastomas. Originating from healthy brain cells, glioblastomas can form in any area of the brain.

Soma Sengupta, MD, PhD, said the trial will administer two immunotherapy drugs in tandem with each other. She noted previous research has shown a single-arm immunotherapy treatment has not been effective, leading to the combination therapy being tested in the trial.

In collaboration with the Dana-Farber Cancer Insitute in Boston, a teaching affiliate of Harvard Medical School, researchers aim to enroll 24 patients in the Phase 1 study.

Read the article.

Read more about the trial.

For more trial and enrollment information, contact Alex Love at

Featured photo at top of glioblastoma cells in culture courtesy of National Cancer Institute.

Related Stories


Local 12: UC startup gains approval for trials

May 30, 2023

A startup founded by four University of Cincinnati physicians gained FDA approval to move forward with clinical trials for its portable system that can detect brain injuries, Local 12 reported.


WLWT: How one of Ohio’s newest lawyers went from federal prison...

May 30, 2023

UC Law alum Damon Davis spoke with WLWT-TV about his journey from former federal prison inmate to accomplished attorney. Davis spent four-and-a-half years behind bars after being convicted of federal drug and gun charges in 2017. This month he took the Ohio Bar Admissions and is now a public defender in Hamilton County.


Newsweek: Conservative justices deal a blow to Ivermectin in...

May 29, 2023

The Wisconsin Supreme Court ruled earlier this month that hospitals can’t be forced to issue Ivermectin to patients. It backed an earlier appeals court decision. Jennifer Bard, PhD, professor at the University of Cincinnati College of Law, weighed in on the decision during an interview with Newsweek.

Debug Query for this